Maplight Therapeutics (NASDAQ:MPLT) Stock: Insider James Woodruff Lillie Sells 11,513 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Lillie sold 11,513 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $8.08, for a total value of $93,025.04. Following the completion of the transaction, the insider owned 198,597 shares in the company, valued at approximately $1,604,663.76. This represents a 5.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James Woodruff Lillie also recently made the following trade(s):

• On Monday, August 3rd, James Lillie sold 22,082 shares of Maplight Therapeutics stock. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28.

Maplight Therapeutics Trading Down 4.0%

Shares of MPLT stock opened at $7.70 on Friday. The firm has a market capitalization of $427.97 million and a PE ratio of -0.18. The firm has a fifty day simple moving average of $11.24 and a two-hundred day simple moving average of $22.37. Maplight Therapeutics, Inc. has a 12 month low of $7.46 and a 12 month high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.08. On average, equities analysts predict that Maplight Therapeutics, Inc. will post -5.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

MPLT has been the subject of several recent research reports. HC Wainwright decreased their target price on shares of Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Canaccord Genuity Group set a $21.00 price target on shares of Maplight Therapeutics in a research report on Friday, August 14th. Craig Hallum reiterated a “buy” rating and set a $25.00 price target on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Benchmark reiterated a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, June 22nd. Finally, BMO Capital Markets started coverage on Maplight Therapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $46.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Maplight Therapeutics News Summary

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: MapLight Therapeutics is described as technically oversold after falling 29.2% over four weeks, potentially creating conditions for a rebound. Wall Street analysts have also been revising earnings estimates higher, providing a possible catalyst for a trend reversal. Down 29.2% in 4 Weeks, Here’s Why You Should You Buy the Dip in MapLight Therapeutics
• Neutral Sentiment: CEO Christopher Kroeger sold 73,691 shares for approximately $595,423, while CFO Jonathan Gillis sold 10,167 shares for approximately $82,149. Both executives retained substantial holdings, and the filings said the sales covered tax obligations tied to equity vesting. CEO Form 4 Filing CFO Form 4 Filing
• Negative Sentiment: Additional insiders Erin Pennock Foff, James Lillie and Anatol Kreitzer sold a combined 39,116 shares for roughly $313,118. Although these were also tax-withholding transactions, the cluster of insider selling can weigh on sentiment and add perceived supply pressure. Erin Pennock Foff Form 4 Filing James Lillie Form 4 Filing Anatol Kreitzer Form 4 Filing

Institutional Investors Weigh In On Maplight Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Maplight Therapeutics during the 2nd quarter valued at $36,741,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics during the 2nd quarter worth $34,809,708. 5AM Venture Management LLC bought a new stake in shares of Maplight Therapeutics in the 2nd quarter worth $34,048,394. Blue Owl Capital Holdings LP bought a new stake in shares of Maplight Therapeutics in the 2nd quarter worth $26,161,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Maplight Therapeutics in the 1st quarter worth $7,622,000.

About Maplight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects.

MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders.

The company conducts research and clinical development in the United States.